{
    "clinical_study": {
        "@rank": "159807", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Optional Cohort 4", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Optional Cohort 5", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the safety and plasma concentrations of PF-06412562 in\n      healthy volunteers following three times daily oral dosing of PF-06412562 for 14 days"
        }, 
        "brief_title": "A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy female subjects of non-childbearing potential and/or male subjects between\n             the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant\n             abnormalities identified by a detailed medical history, full physical examination,\n             including blood pressure and pulse rate measurement, 12-lead ECG and clinical\n             laboratory tests).\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs);\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at time of dosing).\n\n          -  Other severe acute or chronic medical or psychiatric condition or laboratory\n             abnormality that may increase the risk associated with study participation or\n             investigational product administration or may interfere with the interpretation of\n             study results and, in the judgment of the investigator, would make the subject\n             inappropriate for entry into this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959594", 
            "org_study_id": "B7441002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days", 
                "intervention_name": "3 mg PF-06412562", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days", 
                "intervention_name": "10 mg PF-06412562", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days", 
                "intervention_name": "25 mg PF-06412562", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Optional Cohort 4", 
                "description": "oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts", 
                "intervention_name": "PF-06412562 TBD mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Optional Cohort 5", 
                "description": "oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts", 
                "intervention_name": "PF-06412562 TBD mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "multiple doses", 
            "pharmacokinetics", 
            "safety", 
            "tolerability", 
            "healthy volunteers", 
            "steady state", 
            "cognitive impairment associated with schizophrenia"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7441002&StudyName=A%20Study%20To%20Observe%20Safety%20And%20Blood%20Concentrations%20Of%20PF-06412562%20During%20And%20Following%20The%20Oral%20Administration%20Of%20Multiple%20Doses%20Of%20PF"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of PF-06412562 In Healthy Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and toleration assessed by: adverse events, supine and standing vital sign measurements, electrocardiogram (ECG) standard 12 lead, blood and urine safety laboratory tests ,CogState and C-SSRS.", 
                "safety_issue": "Yes", 
                "time_frame": "0-15 days"
            }, 
            {
                "measure": "Pharmacokinetics:  Cmax, Tmax, AUC\u03c4 Ctrough, PTR,  Rac on Cmax and AUC\u03c4  t1/2, CL/F, PTR,", 
                "safety_issue": "No", 
                "time_frame": "0-15 days"
            }, 
            {
                "measure": "CogState at followup", 
                "safety_issue": "Yes", 
                "time_frame": "22-25 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959594"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}